bioihbjkbjnl/mcl2 huggingface dataset:
Lower Uterine Segment Thickness and Term Pain,Previous Cesarean Section
Condition: Cesarean Section; Dehiscence; Cesarean Section Complications
Study type: Observational

Summary: 
      the purpose of the researchers; The aim of this study is to evaluate the consistency of niche
      dimensions measured by ultrasonography with visual measurement of the surgeon during the
      operation of the patient when presenting with pain in her current pregnancy.

      If patients who have had previous cesarean section present to the emergency department with
      pain or NST pain, a panic occurs immediately for operation. Purpose of researchers; The aim
      of this study is to investigate whether a really fine determination of the thickness of the
      old incision line is associated with full-thickness rupture or incomplete rupture, which
      appears to be an operation, and if a relationship is found, there is a limit for this
      thickness.
    


Intervention name(s): Measure niche thickness with ultrasound
Intervention type(s): Procedure
Intervention description(s): in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        In Pregnant Women with Term Pain and Previous Cesarean Section; Patients with visual
        evaluation of the lower uterine segment thickness and ultrasound
Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase
Condition: Overweight; Obesity
MeSH terms: Overweight
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to test the safety and effectiveness of a purified extract of
      CH-19 Sweet, containing capsinoids.
    


Intervention name(s): Chronic consumption of chili pepper extract; Chronic consumption of matching placebo
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): 6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.; 0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Body weight; Body composition; Resting metabolic rate and fat oxidation in men; class I obese
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Condition: Posterior Blepharitis; Meibomian Gland Dysfunction
MeSH terms: Meibomian Gland Dysfunction; Blepharitis
Study type: Interventional
Phase: Phase 2

Summary: 
      This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating
      posterior blepharitis associated with Meibomian Gland Disease (MGD)
    

Detailed description: 
      AXR201901 is a multicenter, randomized, double-masked, vehicle-controlled study of AXR-270
      cream and AXR-270 vehicle in subjects with signs and symptoms of posterior blepharitis
      associated with meibomian gland dysfunction
    

Intervention name(s): AXR-270 Low Dose; AXR-270 High Dose; AXR-270 Vehicle
Intervention type(s): Drug; Drug; Drug
Intervention description(s): AXR-270 Topical Eyelid Cream; AXR-270 Topical Eyelid Cream; AXR-270 Topical Eyelid Cream Vehicle
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Meibomian Gland Dysfunction; Posterior Blepharitis
A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
Condition: Down Syndrome
MeSH terms: Down Syndrome; Syndrome
Study type: Interventional
Phase: Phase 2

Summary: 
      This multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study
      will evaluate the efficacy and safety of RG1662 in adults and adolescents with Down syndrome.
      Subjects will be randomized to receive RG1662 either at low or high dose or placebo orally
      twice daily for 26 weeks.
    


Intervention name(s): Placebo; RG1662; RG1662
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Orally twice daily, 26 weeks; 120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks; 240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
Condition: Muscular Atrophy, Spinal
MeSH terms: Muscular Atrophy; Muscular Atrophy, Spinal; Atrophy
Study type: Interventional
Phase: Phase 2

Summary: 
      Multi-center, randomized, double-blind, placebo-controlled study to assess the safety,
      tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and
      pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an
      exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part
      (Part 2) of Risdiplam for 24 months.
    


Intervention name(s): Placebo; Risdiplam
Intervention type(s): Drug; Drug
Intervention description(s): Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).; Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
Other intervention name(s): RO7034067
Intervention MeSH terms: Risdiplam
Allocation: Randomized
Intervention model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Dynamic Characterisation of Meibomian Gland Structure
Condition: Visual Acuity
Study type: Observational

Summary: 
      This will be a single center pilot study to evaluate appearance of the Meibomian glands.
    


Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Subjects will be recruited and enrolled based on Inclusion/Exclusion criteria
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
Condition: Chronic Hepatitis C
MeSH terms: Hepatitis C; Hepatitis C, Chronic
Study type: Interventional
Phase: Phase 1

Summary: 
      This is an open-label, two-group, fixed-sequence study to evaluate the effect of ACH-3102 and
      Simeprevir on AL-335 pharmacokinetics in healthy volunteers.
    


Intervention name(s): AL-335; ACH-3102; Simeprevir
Intervention type(s): Drug; Drug; Drug
Intervention description(s): AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.; ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.; Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
Other intervention name(s): Olysio
Intervention MeSH terms: Simeprevir; Odalasvir
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Is it Possible to Replace Fentanyl in Anesthesia for Minor Procedures?
Condition: Anesthesia
Study type: Interventional

Summary: 
      To compare between fentanyl group and ketamine lidocaine group for induction of anesthesia as
      regards hemodynamics and smooth intubation.
    

Detailed description: 
      Two groups each with 60 patients Group I anesthesia initiated by propofol, fentanyl and
      cisatracurium. Group II anesthesia initiated by ketamine, lidocaine, propofol and
      cisatracurium.
    

Intervention name(s): Ketamine; Propofol; Fentanyl; Cisatracurium; Lidocaine
Intervention type(s): Drug; Drug; Drug; Drug; Drug
Intervention description(s): ketamine; propofol; fentanyl; cisatracurium; lidocaine
Intervention MeSH terms: Lidocaine; Fentanyl; Ketamine; Propofol; Cisatracurium
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary purpose: Prevention
Keywords: fentanyl; lidocaine; ketamine; induction of anesthesia; intubation
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study
Condition: Body Dysmorphic Disorders; Anorexia
MeSH terms: Anorexia; Anorexia Nervosa; Body Dysmorphic Disorders
Study type: Interventional

Summary: 
      The place of opioid system in anorexia nervosa (AN) physiopathology is still unclear.
      Conflicting results were published on cerebral spinal fluid or peripheral levels in anorexia
      nervosa. However, no data have been reported on opioid cerebral activity. Diprenorphine is a
      ligand with non-selective binding to opiate receptors µ, κ and δ capable to assess the
      interaction between endogenous opioids and their receptors.
    


Intervention name(s): Positron Emission Tomography using [11C]diprenorphine
Intervention type(s): Drug
Intervention description(s): PET using [11C]diprenorphine
Other intervention name(s): PET
Intervention MeSH terms: Diprenorphine
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: anorexia nervosa; opioid receptors; Positron emission tomography (PET); diprenorphine
The Effects of Weight Loss on Psoriatic Arthritis
Condition: Psoriatic Arthritis; Obesity
MeSH terms: Arthritis; Arthritis, Psoriatic
Study type: Interventional

Summary: 
      Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Although
      the underlying cause of PSA is unclear, increased body weight is known to increase the
      disease symptoms. This study aims to determine the effects of dietary and Cognitive Exercise
      Therapy Approach (BETY-Bilişsel Egzersiz Terapi Yöntemi) interventions on symptoms.
      Accordingly, 45 overweight/obese subjects with PSA aged 20-65 years will divide into "diet",
      "diet+bety", and "control" groups. Dietary, laboratory and anthropometric records, Short Form
      Health Survey, DAPSA (Disease Activity in Psoriatic Arthritis), HAQ (Health Assesment
      Questionnaire) of all subjects will compare at the baseline and at the end of the study.
    

Detailed description: 
      Although the underlying cause of PSA is unclear, increased body weight is known to increase
      the disease symptoms. The present study aims to determine the effects of dietary and
      Cognitive Exercise Therapy Approach interventions on symptoms.

        -  Fourt-five overweight/obese subjects with PSA aged 20-65 years will divide into diet
           (n=15), diet+bety (n=15), and control (n=15) groups.

        -  Individually diet programs will be applied according to the metabolic, biochemical, and
           physical activity status of the subjects prepared by a registered dietitian.

        -  BETY exercise training will be given by a registered physiotherapist.

        -  The subjects will be followed for 12 weeks.

        -  Dietary, laboratory and anthropometric records, Short Form Health Survey, DAPSA (Disease
           Activity in Psoriatic Arthritis), HAQ (Health Assesment Questionnaire) of all subjects
           will compare at the baseline and at study completion.
    

Intervention name(s): diet and biopsychosocial exercise intervention
Intervention type(s): Behavioral
Intervention description(s): dietary intervention: biopsychosocial exercise intervention:
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Keywords: psoriatic arthritis; diet; biopsychosocial exercise
Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects
Condition: Hypertriglyceridmia
Study type: Interventional
Phase: Phase 1

Summary: 
      Once a day oral administration with DCCR is the optimal dosing regimen
    

Detailed description: 
      POPULATION The population will consist of generally healthy subjects with elevated fasting
      triglyceride levels in the range of ≥ 150 mg/dL and ≤ 1500 mg/dL at the Screening Visit.

      Number of Subjects A total of 10 subjects will be enrolled in the study at 1 site in the USA.
    

Intervention name(s): Diazoxide Choline Controlled-Release Tablet
Intervention type(s): Drug
Intervention description(s): DCCR 290 mg once a day for 10 days
Intervention MeSH terms: Diazoxide; Choline
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Keywords: DCCR; Diazoxide Chonline Controlled-Release Tablet = DCCR; Hypertriglyceridemia; Triglycerides; Pharmacokinetics
A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study is to evaluate the effect of 5 different food conditions on the
      single dose pharmacokinetics (PK) of the JNJ-64417184 tablet formulation administered orally,
      using the PK after a high-fat meal as a reference, in healthy adult participants.
    


Intervention name(s): JNJ-64417184
Intervention type(s): Drug
Intervention description(s): Participants will receive single dose of JNJ-64417184 as oral tablet.
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Neuroform Atlas Stent System Study
Condition: Intracranial Aneurysm
MeSH terms: Intracranial Aneurysm; Aneurysm
Study type: Interventional

Summary: 
      The primary objective of this study is to demonstrate effectiveness and safety of the
      Neuroform Atlas Stent System for use with bare metal embolic coils.
    

Detailed description: 
      The study is a prospective, multicenter, open-label, single arm trial designed to demonstrate
      the potential treatment of wide neck, intracranial, saccular aneurysms with the Next
      Generation Neuroform Stent System with any approved embolic coils currently on the market.
      The study will evaluate the percent occlusion of the treated target lesion on angiography in
      the absence of retreatment, or parent artery stenosis at the target location at 12 months.
      Subjects with documented wide neck, intracranial, saccular aneurysms arising from a parent
      artery may potentially benefit from stent assisted coiling, provided they meet the other
      eligibility criteria.

      Data collected through the 12-month follow-up visit are intended to support Premarket
      Approval (PMA) application to the Food and Drug Administration (FDA). Long-term follow-up
      data collected through 3 years postoperative are intended to support post-approval study
      (PAS) requirements.
    

Intervention name(s): Next Generation Neuroform Stent System
Intervention type(s): Device
Intervention description(s): The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Next Generation Neuroform Stent System; Wide Neck, Intracranial, Saccular Aneurysms; Cerebral Aneurysms
Normal Variability of Tidal Breathing Flow-volume Curves During Sleep in Healthy Children
Condition: Respiration Disorders
MeSH terms: Respiration Disorders
Study type: Observational

Summary: 
      The study includes a comprehensive health examination with focus on respiratory health and
      the TBFV recordings using impedance pneumography (Ventica®) during sleep at night in healthy
      children.
    

Detailed description: 
      Impedance pneumograpy results in healthy children to generate normal values and to stude the
      effect of age and gender
    

Intervention name(s): Ventica
Intervention type(s): Diagnostic Test
Intervention description(s): Impedance pneumography measurement
Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Sample of 40 healthy children aged 12 - 71 months.
Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This study is a phase 1 study of PF-06651600. PF-06651600 is being developed for treatment of
      inflammatory bowel disease. The goal of the study is to assess the safety, tolerability,
      pharmacokinetics and pharmacodynamics of PF-06651600 after multiple oral doses of PF-06651600
      in Japanese healthy volunteers.
    


Intervention name(s): PF-06651600; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): PF-06651600 will be administered as tablet; Matching placebo will be administered as tablet
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
Condition: Behavior; Anxiety
Study type: Interventional
Phase: Phase 4

Summary: 
      Subjects-currently in outpatient mental health care--will participate in 2 psychotherapy
      sessions, one with oxytocin spray and one with placebo spray. Sessions will be videotaped,
      and cortisol and heart rate will be measured. We hypothesize that oxytocin will have positive
      benefits on nonverbal behavior in the therapy session, as well as have positive effects on
      subjective anxiety, cortisol and heart rate.
    


Intervention name(s): Placebo then intranasal oxytocin; Intranasal oxytocin then placebo
Intervention type(s): Drug; Drug
Intervention description(s): Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.; Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
Intervention MeSH terms: Oxytocin
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: psychotherapy
Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major
Condition: Beta Thalassemia
MeSH terms: Thalassemia; beta-Thalassemia
Study type: Interventional

Summary: 
      The aim of this study is to evaluate the cardioprotective effect of spirulina in children
      with beta thalassemia.
    

Detailed description: 
      The aim of this study is to evaluate the cardioprotective effect of spirulina in children
      with beta thalassemia.

      this study will be carried on thirty children with beta thalassemia major from those
      attending the Hematology Unit of Pediatric department at Tanta University Hospital, and
      another thirty healthy children of matched age and sex will be enrolled as controls.

      all studied children will be subjected to careful history taking and through clinical
      examination. laboratory investigations will be done including complete blood count,
      hemoglobin electrophoresis, serum ferritin, liver and kidney functions, and troponin-1 plasma
      level. echocardiographic assessment of the cardiac functions will be done for all patients.
      Source data will be the patients medical records.

      oral spirulina will be given for studied patients for 3 months, and clinical examination,
      laboratory investigations and cardiac functions will be assessed at the time of inclusion in
      the study, and again after 3 months of regular spirulina supplementation.

      An informed consent will be obtained from parents of all included subjects. the results of
      this study will be tabulated and statistically analyzed using Statistical Package for the
      Social Sciences (SPSS).
    

Intervention name(s): spirulina
Intervention type(s): Other
Intervention description(s): oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Care Provider)
Primary purpose: Prevention
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Condition: Alzheimer's Disease; Dementia, Alzheimer Type
MeSH terms: Alzheimer Disease; Dementia
Study type: Interventional
Phase: Phase 3

Summary: 
      The goal of this research study is to evaluate the safety and efficacy of the rivastigmine
      transdermal patch in patients with probable Alzheimer's Disease.
    


Intervention name(s): rivastigmine transdermal patch
Intervention type(s): Drug
Intervention MeSH terms: Rivastigmine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Alzheimer's Disease; Dementia
Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional
Phase: Phase 4

Summary: 
      The primary objective of this study is to compare the efficacy and safety of budesonide HFA
      MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID in Chinese
      mild to moderate Asthma patients.
    

Detailed description: 
      A total of 270 Chinese mild to moderate Asthma patients will be enrolled and 230 will be
      completed in this multi-center, randomized, single blind, parallel efficacy and safety
      comparison study of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler)
      100 mcg 4 puffs BID.
    

Intervention name(s): Budesonide 200 microgram/Puff, HFA MDI; Budesonide 100 microgram/Actuation Powder for Inhalation
Intervention type(s): Drug; Drug
Intervention description(s): Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.; Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
Other intervention name(s): Duasma 200 mcg inhaler; Pulmicort 100 mcg Turbuhaler
Intervention MeSH terms: Budesonide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: budesonide; MDI; DPI; China; Asthma